Elizabeth A. Thiele MD, PhD

Two experts explain the impact of the drug fenfluramine’s FDA approval in the treatment of Dravet syndrome.

Drs Thiele and Wirrell continue analyzing the benefits of cannabidiol as a therapeutic option for patients with Dravet or Lennox-Gastaut syndromes.

The panelists discuss the possibility of treating Dravet syndrome in older children and adults and the effects if the therapies were effective.  

The panel discusses future gene therapies in development for Dravet syndrome.

Elaine Wirrell, MD, reviews the transition of care into adulthood of patients with Dravet syndrome and how this transition can affect the patient, caregiver, and care provider.

The panel discusses the impact on the family, siblings, or caregivers of patients with Dravet syndrome.

Elaine Wirrell, MD, provides background on fenfluramine, results from 2 clinical trials, and compares it to other treatment therapies.

Elizabeth Thiele, MD, PhD, reviews cannabidiol oral solution as treatment of seizures associated with Dravet syndrome and the safety profile and dosing associated with it.

Experts in the field discuss second- and third-line treatment options for Dravet syndrome such as stiripentol and vagal nerve stimulation and the effects they’ve seen on patients.

A panel discussion on the North American Consensus statement on treating Dravet syndrome and the approved therapies like clobazam, ketogenic diets, and other first- and second-line therapies.

Elizabeth Thiele, MD, PhD, and Peter Crino, MD, PhD, provide closing remarks on the future treatment landscape of tuberous sclerosis complex. 

Advice to community neurologists for the optimal care of patients with tuberous sclerosis complex and future directions for TSC. 

A discussion on having conversations with the parents of patients with Dravet syndrome with regards to adjustments to therapy and managing their expectations.

A panel of experts discuss treatment goals for patients with Dravet syndrome and how to convey the variability of treatment to the parents of these patients.

Expert neurologists and epileptologists share best practices for transitioning a patient with TSC from adolescence into adulthood.

Elizabeth Thiele, MD, PhD, and Peter Crino, MD, PhD, comment on unmet needs and challenges in treating tuberous sclerosis complex.

Trevor J. Resnick, MD, and Elaine Wirrell, MD, explain why the early diagnosis of Dravet syndrome is important, which patient profiles should be noted for ordering genetic testing, and what to do with those results.  

Elizabeth Thiele, MD, PhD, and Elaine Wirrell, MD, provide an overview of Dravet syndrome and the seizure triggers in pediatric patients.

Peter Crino, MD, PhD, leads the discussion on exciting developments in approved therapies for managing seizures in TSC including the use of everolimus and cannabidiol.

Peter Crino, MD, PhD, and Elizabeth Thiele, MD, PhD, review the spectrum of epilepsy in patients with TSC and approaching the treatment of seizures.

Experts in neurology discuss recommendations for genetic testing when approaching the diagnosis of TSC and misconceptions around cognitive impairment.

Peter Crino, MD, PhD, and Elizabeth Thiele, MD, PhD, review the major and minor diagnostic criteria for TSC based on the 2012 International Tuberous Sclerosis Complex Consensus Recommendations.

Expert neurologists discuss the clinical presentation and diagnosis of tuberous sclerosis complex.

Elizabeth Thiele, MD, PhD, and Peter Crino, MD, PhD, define tuberous sclerosis complex (TSC) including the neurobehavioral manifestations of disease.